Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: AGR002
MIFTS: 47

Agoraphobia

Categories: Mental diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Agoraphobia

About this section

MalaCards integrated aliases for Agoraphobia:

Name: Agoraphobia 12 76 55 44 15 73
Fear of Open Spaces 12

Classifications:

MalaCards categories:
Anatomical: Mental diseases
See all MalaCards categories (disease lists)
ICD10: 33


External Ids:

Disease Ontology 12 DOID:593
ICD10 33 F40.0 F40.00
MeSH 44 D000379
NCIt 50 C34362
SNOMED-CT 68 70691001
UMLS 73 C0001818
Sources

Summaries for Agoraphobia

About this section
Disease Ontology : 12 A phobic disorder involving the specific anxiety about being in a place or situation where escape is difficult or embarrassing or where help may be unavailable.

MalaCards based summary : Agoraphobia, also known as fear of open spaces, is related to depression and social phobia. An important gene associated with Agoraphobia is HTR1A (5-Hydroxytryptamine Receptor 1A), and among its related pathways/superpathways are Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways and Serotonergic synapse. The drugs Paroxetine and Clonazepam have been mentioned in the context of this disorder. Affiliated tissues include cortex, testes and bone, and related phenotypes are behavior/neurological and cardiovascular system

Wikipedia : 76 Agoraphobia is an anxiety disorder characterized by symptoms of anxiety in situations where the person... more...

Sources

Related Diseases for Agoraphobia

About this section

Diseases related to Agoraphobia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 78)
# Related Disease Score Top Affiliating Genes
1 depression 31.1 HTR1A MAOA SLC6A4
2 social phobia 30.9 HTR1A MAOA SLC6A4
3 panic disorder 30.8 CCKBR GLRB HTR1A MAOA PTK7 SLC6A2
4 personality disorder 30.8 HTR1A MAOA SLC6A4
5 anxiety 30.8 CCKBR HTR1A MAOA PTK7 SLC6A4
6 obsessive-compulsive disorder 30.6 HTR1A MAOA SLC6A4
7 phobic disorder 30.4 GLRB HTR1A MAOA OPRK1 PIR PTK7
8 generalized anxiety disorder 30.4 HTR1A MAOA SLC6A2 SLC6A4
9 atypical depressive disorder 30.0 MAOA SLC6A4
10 schizophrenia 30.0 HTR1A MAOA SLC6A2 SLC6A4
11 major depressive disorder 29.6 HTR1A MAOA SLC6A2 SLC6A4
12 alcohol dependence 29.4 HTR1A MAOA OPRK1 SLC6A4
13 panic disorder 1 11.3
14 psychosexual disorder 10.2 HTR1A SLC6A4
15 sexual disorder 10.2 HTR1A SLC6A4
16 periodic limb movement disorder 10.2 HTR1A SLC6A4
17 premature ejaculation 10.2 HTR1A SLC6A4
18 eating disorder 10.2
19 avoidant personality disorder 10.2 MAOA SLC6A4
20 alexithymia 10.2 HTR1A SLC6A4
21 intermittent explosive disorder 10.2 HTR1A SLC6A4
22 pathological gambling 10.2 MAOA SLC6A4
23 antisocial personality disorder 10.1 MAOA SLC6A4
24 migraine without aura 10.1 HTR1A SLC6A4
25 paranoid schizophrenia 10.1 MAOA SLC6A4
26 postpartum depression 10.1 MAOA SLC6A4
27 neurotic disorder 10.1 GLRB HTR1A
28 bipolar i disorder 10.1 HTR1A SLC6A4
29 kleptomania 10.1 HTR1A MAOA SLC6A4
30 brunner syndrome 10.1 HTR1A MAOA SLC6A4
31 schizoid personality disorder 10.1 HTR1A PIR
32 borderline personality disorder 10.1 HTR1A MAOA SLC6A4
33 serotonin syndrome 10.1 HTR1A MAOA SLC6A4
34 endogenous depression 10.1 HTR1A MAOA SLC6A4
35 chronic fatigue syndrome 10.1 HTR1A MAOA SLC6A4
36 separation anxiety disorder 10.1
37 hyperthyroidism 10.1
38 dyspepsia 10.1 HTR1A SLC6A4
39 migraine with or without aura 1 10.1 HTR1A MAOA SLC6A4
40 dopamine beta-hydroxylase deficiency, congenital 10.1 MAOA SLC6A2
41 sudden infant death syndrome 10.1 HTR1A MAOA SLC6A4
42 dependent personality disorder 10.1 MAOA PIR
43 cocaine abuse 10.0 SLC6A2 SLC6A4
44 oppositional defiant disorder 10.0 MAOA SLC6A2 SLC6A4
45 orthostatic intolerance 10.0
46 hypochondriasis 10.0
47 melancholia 10.0
48 irritable bowel syndrome 10.0
49 dysthymic disorder 10.0 MAOA PIR SLC6A4
50 autism 9.9 GRPR HTR1A MAOA SLC6A4

Graphical network of the top 20 diseases related to Agoraphobia:



Diseases related to Agoraphobia
Sources

Symptoms & Phenotypes for Agoraphobia

About this section

MGI Mouse Phenotypes related to Agoraphobia:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.86 CCKBR GLRB GRPR HTR1A MAOA OPRK1
2 cardiovascular system MP:0005385 9.76 CCKBR GLRB HTR1A MAOA PTK7 SLC6A2
3 homeostasis/metabolism MP:0005376 9.61 CCKBR GLRB GRPR HTR1A MAOA OPRK1
4 nervous system MP:0003631 9.28 CCKBR GLRB HTR1A MAOA OPRK1 PTK7
Sources

Drugs & Therapeutics for Agoraphobia

About this section

Drugs for Agoraphobia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 65)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Paroxetine Approved, Investigational Phase 4,Phase 3 61869-08-7 43815
2
Clonazepam Approved, Illicit Phase 4 1622-61-3 2802
3
Sertraline Approved Phase 4 79617-96-2 68617
4
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
5
Citalopram Approved Phase 4 59729-33-8 2771
6
Alprazolam Approved, Illicit, Investigational Phase 4,Phase 1 28981-97-7 2118
7 GABA Agents Phase 4,Phase 1
8 Psychotropic Drugs Phase 4,Phase 3,Phase 1
9 Antidepressive Agents Phase 4,Phase 3,Not Applicable
10 Antidepressive Agents, Second-Generation Phase 4,Phase 3
11 Cytochrome P-450 CYP2D6 Inhibitors Phase 4,Phase 3
12 Serotonin Uptake Inhibitors Phase 4,Phase 3
13 Anticonvulsants Phase 4
14 Serotonin Agents Phase 4,Phase 3
15 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3
16 Neurotransmitter Agents Phase 4,Phase 3,Phase 1,Not Applicable
17 Neurotransmitter Uptake Inhibitors Phase 4,Phase 3
18 GABA Modulators Phase 4,Phase 1
19 Lisdexamfetamine Dimesylate Phase 4
20 Dopamine Uptake Inhibitors Phase 4
21 Central Nervous System Stimulants Phase 4
22 Dopamine Agents Phase 4
23 Autonomic Agents Phase 4
24 Muscarinic Antagonists Phase 4
25 Antiparkinson Agents Phase 4
26 Peripheral Nervous System Agents Phase 4
27 Cholinergic Antagonists Phase 4
28 Cholinergic Agents Phase 4
29 Parasympatholytics Phase 4
30 Central Nervous System Depressants Phase 4,Phase 1
31 Anti-Anxiety Agents Phase 4,Phase 1,Not Applicable
32 Hypnotics and Sedatives Phase 4,Phase 1
33 Tranquilizing Agents Phase 4,Phase 1
34 Immunoglobulins, Intravenous Phase 4
35 gamma-Globulins Phase 4
36 Rho(D) Immune Globulin Phase 4
37 Immunologic Factors Phase 4
38 Antibodies Phase 4
39 Immunoglobulins Phase 4
40
Serotonin Investigational, Nutraceutical Phase 4,Phase 3 50-67-9 5202
41 Sunflower Phase 3
42 Lecithin Phase 3
43
Cycloserine Approved Phase 2 68-41-7 6234 401
44 Anti-Infective Agents Phase 2
45 Antitubercular Agents Phase 2
46 Antibiotics, Antitubercular Phase 2
47 Anti-Bacterial Agents Phase 2
48 Antimetabolites Phase 2
49 Anti-Infective Agents, Urinary Phase 2
50 Renal Agents Phase 2

Interventional clinical trials:

(show top 50) (show all 86)
# Name Status NCT ID Phase Drugs
1 Long Term Treatment of Panic Disorder With Clonazepam or Paroxetine Completed NCT02852577 Phase 4 Clonazepam;Paroxetine
2 A Study Of Sertraline Compared With Paroxetine In The Treatment Of Panic Disorder Completed NCT00677352 Phase 4 sertraline;Paroxetine
3 Paroxetine vs Placebo Combined With Aerobic Exercise or Relaxation in Panic Disorder Completed NCT00540098 Phase 4 paroxetine + aerobic exercise;Paroxetine + relaxation;Placebo + aerobic exercise;Placebo + relaxation
4 Lisdexamfetamine Dimesylate in the Treatment of Adult ADHD With Anxiety Disorder Comorbidity Completed NCT01863459 Phase 4 Lisdexamfetamine Dimesylate;placebo
5 Treatments for Anxiety: Meditation and Escitalopram Recruiting NCT03522844 Phase 4 Escitalopram
6 A Study to Evaluate the Benefit of Octagam 5%® in Subjects With Pediatric Acute-onset Neuropsychiatric Syndrome (PANS) Active, not recruiting NCT03348618 Phase 4
7 A 14 Week, Randomized, Placebo-Controlled Cross-Over Study of Methylphenidate Hydrochloride Controlled Release Capsules in Adult ADHD With and Without Anxiety Disorder Comorbidity Not yet recruiting NCT03785223 Phase 4 Methylphenidate Hydrochloride Controlled-Release Capsules;Placebo Capsule
8 A Study To Assess the Safety of Extended Release Alprazolam for the Treatment of Adolescents With Panic Disorder or Anxiety With Panic Attacks Terminated NCT00634790 Phase 4 alprazolam XR
9 Sertraline in Generalized Social Phobia With Co-Occurring Anxiety and Mood Disorders Terminated NCT00182533 Phase 4 Sertraline;Placebo
10 Mechanisms of Panic Disorders Treatment Unknown status NCT01323556 Phase 2, Phase 3
11 Treatment of Panic Disorder: Long Term Strategies Completed NCT00000368 Phase 3 Paroxetine or other medication - algorithm used
12 Comparison of Psychotherapy Programs to Treat Panic Disorder Completed NCT00353470 Phase 3
13 Internet-Versus Group-Administered Cognitive Behavior Therapy for Panic Disorder Completed NCT00845260 Phase 3
14 Treatment of Social Phobia and Panic Disorder in Adults Completed NCT00619138 Phase 3
15 Effects of Prismatic Spectacle Lenses on Symptoms of Dizziness, Headache and Anxiety as Caused by Vertical Heterophoria Completed NCT00785135 Phase 3
16 Cannabidiol for the Treatment of Anxiety Disorders: An 8-Week Pilot Study Not yet recruiting NCT03549819 Phase 3 Cannabidiol (CBD) Oil Capsules;Sunflower Lecithin Oil in Capsule
17 Augmentation of Psychotherapy With D-Cycloserine in Agoraphobia Completed NCT01928823 Phase 2 D-Cycloserine
18 Effectiveness of Intensive Cognitive Behavioral Therapy in Treating Adolescent Panic Disorder and Agoraphobia Completed NCT00576719 Phase 2
19 Exposure Therapy for Fear of Falling in Older Adults Completed NCT01609322 Phase 2
20 Physical Exercise Versus Cognitive-behavioral Therapy (CBT) for Panic Disorders: A Randomised Controlled Trial Completed NCT01076777 Phase 2
21 Effectiveness of Cognitive Behavioral Therapy With Panic Control Treatment for Adolescents With Panic Disorder Completed NCT00705380 Phase 2
22 Improve: Integrating Emotion Focused Components Into Psychological Therapy Active, not recruiting NCT02822443 Phase 2
23 The Modular Protocol for Mental Health (MPMH) Enrolling by invitation NCT03143634 Phase 1, Phase 2
24 An Bioequivalence Study Of Xanax Extended Release Tablets From Two Different Manufacturing Sites Completed NCT01330472 Phase 1 Xanax XR tablets 3 mg (sourced from Caugus);Xanax XR tablets 3 mg (sourced from Barceloneta)
25 Study of Virtual Reality Therapy and Cognitive Behavior Therapy in Panic Disorder With Agoraphobia Unknown status NCT00129610 Not Applicable
26 Providing Tools for Effective Care and Treatment of Anxiety Disorders Unknown status NCT02605668 Not Applicable
27 Virtual Reality and Concept of Control in the Treatment of Acrophobia Unknown status NCT02020824 Not Applicable
28 A Randomised Feasibility Trial With Internet Based Self-help Therapy Unknown status NCT02499055 Not Applicable
29 Effectiveness of Cognitive Behavioral Short-term Treatment for Adolescents With Emotional Symptom Problems in Community Clinics in Norway Unknown status NCT02150265 Not Applicable
30 Transdiagnostic Treatment for Early Stage Mental Health Problems in Youth Unknown status NCT02540746 Not Applicable
31 Prospective Cohort Study of Accelerated Resolution Therapy (ART) for Treatment of Military Psychological Trauma Unknown status NCT02030522 Not Applicable
32 Thought Field Therapy and Cognitive Therapy for Agoraphobia Completed NCT00932919 Not Applicable
33 Physical Activity and Cognitive Behavioural Therapy in Panic Disorder and Agoraphobia Completed NCT01928810 Not Applicable
34 Longterm Outcome of Inpatient Cognitive and Behavioral Therapies for Agoraphobia Completed NCT01446172
35 Mechanisms of Treatment Change in Panic Disorder and Agoraphobia Completed NCT03547180 Not Applicable
36 Virtual Reality Exposure Therapy in Agoraphobic Participants Completed NCT00734370 Not Applicable
37 Cognitive Behavioral Therapy in Panic Disorder Completed NCT00772746
38 Internet-based Exposure Therapy for Panic Disorder Completed NCT03061448 Not Applicable
39 Physical Activity and Cognitive Behavioural Therapy in Panic Disorder Completed NCT01788800 Not Applicable
40 Vestibular Dysfunction In Adult Patients With Panic Disorder With or Without Agoraphobia Completed NCT00004367 Not Applicable
41 Can Thought Field Therapy (TFT) be Helpful for Patients With an Anxiety Disorder? Completed NCT00202709 Not Applicable
42 Cognitive Behavior Psychotherapy in Panic Disorder Completed NCT01025908 Not Applicable
43 Pilot Study of Vestibular Rehabilitation Training for Panic Disorder With Vestibular Dysfunction Completed NCT00004366 Not Applicable
44 Interpretation Modification Program for Social Phobia Completed NCT00684541 Not Applicable
45 Study of the Changes in Metabolic Parameters in Patients Treated With Escitalopram for Six Months Completed NCT00711737
46 Assessment of the Prevalence of Major Psychiatric Disorders in a Cohort of Women With Clinical Criteria Corresponding to Pure, Abortive-form, Obstetrical, Antiphospholipid Syndrome Completed NCT02833194
47 Genetic Causes of Panic Disorder Completed NCT00083265
48 Transversal Multiaxial Evaluation and 5-year Follow-up of a Cohort of French Gamblers (JEU) Completed NCT01207674 Not Applicable
49 Transdiagnostic Psychotherapy for Veterans With Mood and Anxiety Disorders Completed NCT01947647 Not Applicable
50 A Randomized Controlled Trial of PCIT-ED for Preschool Depression Completed NCT02076425 Not Applicable

Search NIH Clinical Center for Agoraphobia

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: agoraphobia

Sources

Genetic Tests for Agoraphobia

About this section
Sources

Anatomical Context for Agoraphobia

About this section

MalaCards organs/tissues related to Agoraphobia:

41
Cortex, Testes, Bone, Brain, Thyroid, Breast, Cingulate Cortex
Sources

Publications for Agoraphobia

About this section

Articles related to Agoraphobia:

(show top 50) (show all 827)
# Title Authors Year
1
Social Support and Symptom Severity Among Patients With Obsessive-Compulsive Disorder or Panic Disorder With Agoraphobia: A Systematic Review. ( 29899808 )
2018
2
The relationship between impulsivity and panic disorder-agoraphobia: The role of affective temperament. ( 29649673 )
2018
3
Stress hormone response to the DEX-CRH test and its relation to psychotherapy outcome in panic disorder patients with and without agoraphobia. ( 29391399 )
2018
4
Bowel and Bladder Anxiety: An Obsession or a Variant of Agoraphobia? ( 29875534 )
2018
5
Running for extinction? Aerobic exercise as an augmentation of exposure therapy in panic disorder with agoraphobia. ( 29539585 )
2018
6
Pretreatment Cardiac Vagal Tone Predicts Dropout from and Residual Symptoms after Exposure Therapy in Patients with Panic Disorder and Agoraphobia. ( 29533952 )
2018
7
Predictors of remission from panic disorder, agoraphobia and specific phobia in outpatients receiving exposure therapy: The importance of positive mental health. ( 29981937 )
2018
8
Hypovitaminosis D is associated with negative symptoms, suicide risk, agoraphobia, impaired functional remission, and antidepressant consumption in schizophrenia. ( 30078128 )
2018
9
Integration of EMDR and CBT Techniques in Treatment of Panic Disorder with Agoraphobia - A Case Report. ( 30095822 )
2018
10
Learn to forget: Does post-exposure administration of d-cycloserine enhance fear extinction in agoraphobia? ( 30237105 )
2018
11
Suicidal ideation in primary care patients suffering from panic disorder with or without agoraphobia. ( 30249220 )
2018
12
Effects of Cognitive Behavioral Therapy on Neural Processing of Agoraphobia-Specific Stimuli in Panic Disorder and Agoraphobia. ( 30269148 )
2018
13
The impact of depressive comorbidity on neural plasticity following cognitive-behavioral therapy in panic disorder with agoraphobia. ( 30428445 )
2018
14
Subclinical Agoraphobia Symptoms and Regional Brain Volumes in Non-clinical Subjects: Between Compensation and Resilience? ( 30546323 )
2018
15
Fear of Fear and Broad Dimensions of Psychopathology over the Course of Cognitive Behavioural Therapy for Panic Disorder with Agoraphobia in Japan. ( 29259145 )
2017
16
Reduction in Costs after Treating Comorbid Panic Disorder with Agoraphobia and Generalized Anxiety Disorder. ( 28418834 )
2017
17
Thought Field Therapy Compared to Cognitive Behavioral Therapy and Wait-List for Agoraphobia: A Randomized, Controlled Study with a 12-Month Follow-up. ( 28676782 )
2017
18
No Effects of D-Cycloserine Enhancement in Exposure With Response Prevention Therapy in Panic Disorder With Agoraphobia: A Double-Blind, Randomized Controlled Trial. ( 28820746 )
2017
19
Psychoticism in patients with panic disorder with or without comorbid agoraphobia. ( 28345374 )
2017
20
Two Novel Cognitive Behavioral Therapy-Based Mobile Apps for Agoraphobia: Randomized Controlled Trial. ( 29175809 )
2017
21
Burden and Distress in Caregivers of Patients With Panic Disorder and Agoraphobia. ( 27861457 )
2017
22
Agoraphobia and Follicle-Stimulating Hormone Levels between Tamoxifen and Goserelin versus Tamoxifen Alone in Premenopausal Hormone Receptor-Positive Breast Cancer: A 12-Month Prospective Randomized Study. ( 28845177 )
2017
23
Support Vector Machine Analysis of Functional Magnetic Resonance Imaging of Interoception Does Not Reliably Predict Individual Outcomes of Cognitive Behavioral Therapy in Panic Disorder with Agoraphobia. ( 28649205 )
2017
24
Neurobiological and clinical effects of fNIRS-controlled rTMS in patients with panic disorder/agoraphobia during cognitive-behavioural therapy. ( 29085773 )
2017
25
Comorbidity and Suicidality in Patients Diagnosed with Panic Disorder/Agoraphobia and Major Depression. ( 28636577 )
2017
26
Transdiagnostic group CBT vs. standard group CBT for depression, social anxiety disorder and agoraphobia/panic disorder: Study protocol for a pragmatic, multicenter non-inferiority randomized controlled trial. ( 28114915 )
2017
27
PanelA Report, IPA Congress Buenos Aires 2017: Claustro-agoraphobia, Bertram Lewin, and the oral triad 6 April 2017. ( 29148571 )
2017
28
The Mobility Inventory for Agoraphobia Avoidance Alone Scale: Factor Structure and Psychometric Properties of Subscales. ( 27449053 )
2016
29
Sustained Resolution of Panic Disorder, Agoraphobia, and Generalized Anxiety Disorder With a Single Ketamine Infusion: A Case Report. ( 27828703 )
2016
30
Facing the fear - clinical and neural effects of cognitive behavioural and pharmacotherapy in panic disorder with agoraphobia. ( 26837851 )
2016
31
Agoraphobia Related to Unassertiveness in Panic Disorder. ( 26915016 )
2016
32
A Comparison of Psychoanalytic Therapy and Cognitive Behavioral Therapy for Anxiety (Panic/Agoraphobia) and Personality Disorders (APD Study): Presentation of the RCT Study Design. ( 27594602 )
2016
33
Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis. ( 27071857 )
2016
34
Cognitive Models for Panic Disorder With Agoraphobia: A Study of Disaggregated Within-Person Effects. ( 27123977 )
2016
35
Agoraphobia With and Without Panic Disorder: A 20-Year Follow-up of Integrated Exposure and Psychodynamic Therapy. ( 26588081 )
2016
36
A discussion of various aspects of panic disorder depending on presence or absence of agoraphobia. ( 27423353 )
2016
37
Panic disorder with agoraphobia from a behavioral neuroscience perspective: Applying the research principles formulated by the Research Domain Criteria (RDoC) initiative. ( 26877119 )
2016
38
Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults. ( 27730622 )
2016
39
Agency and Anxiety: Delusions of Control and Loss of Control in Schizophrenia and Agoraphobia. ( 27725796 )
2016
40
Platzschwindel, agoraphobia and their influence on theories of anxiety at the end of the nineteenth century: theories of the role of biology and 'representations' (Vorstellungen). ( 27450798 )
2016
41
SECOND-STAGE TREATMENTS FOR RELATIVE NONRESPONDERS TO COGNITIVE BEHAVIORAL THERAPY (CBT) FOR PANIC DISORDER WITH OR WITHOUT AGORAPHOBIA-CONTINUED CBT VERSUS SSRI: A RANDOMIZED CONTROLLED TRIAL. ( 26663632 )
2016
42
Threat expectancy bias and treatment outcome in patients with panic disorder and agoraphobia. ( 27061246 )
2016
43
Predictors of Dropout From Cognitive-Behavioral Group Treatment for Panic Disorder With Agoraphobia: An Exploratory Study. ( 27385412 )
2016
44
Insomnia Symptoms Following Treatment for Comorbid Panic Disorder With Agoraphobia and Generalized Anxiety Disorder. ( 27019339 )
2016
45
The role of treatment delivery factors in exposure-based cognitive behavioral therapy for panic disorder with agoraphobia. ( 27235836 )
2016
46
Association of human microRNAs miR-22 and miR-491 polymorphisms with panic disorder with or without agoraphobia in a Korean population. ( 26361067 )
2015
47
Evidence for chronic low-grade systemic inflammation in individuals with agoraphobia from a population-based prospective study. ( 25875094 )
2015
48
Treating Treatment-Resistant Patients with Panic Disorder and Agoraphobia Using Psychotherapy: A Randomized Controlled Switching Trial. ( 25722042 )
2015
49
A systematic review of predictors and moderators of improvement in cognitive-behavioral therapy for panic disorder and agoraphobia. ( 26443228 )
2015
50
An admixture analysis of age of onset in agoraphobia. ( 25898330 )
2015
Sources

Variations for Agoraphobia

About this section
Sources

Expression for Agoraphobia

About this section
Search GEO for disease gene expression data for Agoraphobia.
Sources

Pathways for Agoraphobia

About this section

Pathways related to Agoraphobia according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways 1
11.65 HTR1A MAOA SLC6A4
2
Serotonergic synapse 37
11.39 HTR1A MAOA SLC6A4
3
Monoamine Transport 1
Show member pathways
 10.77 MAOA SLC6A2 SLC6A4
4
Neurotransmitter Clearance In The Synaptic Cleft 66
Show member pathways
 10.74 MAOA SLC6A4
5
Selective Serotonin Reuptake Inhibitor Pathway, Pharmacodynamics 61
10.25 HTR1A MAOA SLC6A4
Sources

GO Terms for Agoraphobia

About this section

Cellular components related to Agoraphobia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 membrane GO:0016020 9.96 CCKBR GLRB GRPR HTR1A MAOA OPRK1
2 plasma membrane GO:0005886 9.92 CCKBR GLRB GRPR HTR1A OPRK1 PTK7
3 integral component of membrane GO:0016021 9.81 CCKBR GLRB GRPR HTR1A MAOA OPRK1
4 integral component of presynaptic membrane GO:0099056 9.4 OPRK1 SLC6A4
5 integral component of postsynaptic membrane GO:0099055 9.37 OPRK1 SLC6A4
6 neuron projection GO:0043005 9.26 GLRB SLC6A2 SLC6A4 STMN1
7 integral component of plasma membrane GO:0005887 9.17 GLRB GRPR HTR1A OPRK1 PTK7 SLC6A2

Biological processes related to Agoraphobia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neuropeptide signaling pathway GO:0007218 9.54 GLRB GRPR OPRK1
2 signal transduction GO:0007165 9.5 CCKBR GLRB GRPR HTR1A OPRK1 PTK7
3 social behavior GO:0035176 9.46 GRPR SLC6A4
4 chemical synaptic transmission GO:0007268 9.46 GLRB HTR1A OPRK1 SLC6A2
5 neurotransmitter transport GO:0006836 9.43 SLC6A2 SLC6A4
6 vasoconstriction GO:0042310 9.4 HTR1A SLC6A4
7 behavior GO:0007610 9.32 HTR1A OPRK1
8 monoamine transport GO:0015844 9.26 SLC6A2 SLC6A4
9 phospholipase C-activating G protein-coupled receptor signaling pathway GO:0007200 8.8 CCKBR GRPR OPRK1

Molecular functions related to Agoraphobia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor activity GO:0004930 9.62 CCKBR GRPR HTR1A OPRK1
2 neuropeptide binding GO:0042923 9.26 GRPR OPRK1
3 neurotransmitter:sodium symporter activity GO:0005328 9.16 SLC6A2 SLC6A4
4 serotonin binding GO:0051378 8.96 HTR1A SLC6A4
5 monoamine transmembrane transporter activity GO:0008504 8.62 SLC6A2 SLC6A4
Sources

Sources for Agoraphobia

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....